These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 27194424)

  • 1. Potassium: friend or foe?
    Rodan AR
    Pediatr Nephrol; 2017 Jul; 32(7):1109-1121. PubMed ID: 27194424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension.
    Kovesdy CP; Appel LJ; Grams ME; Gutekunst L; McCullough PA; Palmer BF; Pitt B; Sica DA; Townsend RR
    J Am Soc Hypertens; 2017 Dec; 11(12):783-800. PubMed ID: 29030153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
    De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Hyperkalemia: Stepping Into a New Frontier.
    Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
    J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension.
    Kovesdy CP; Appel LJ; Grams ME; Gutekunst L; McCullough PA; Palmer BF; Pitt B; Sica DA; Townsend RR
    Am J Kidney Dis; 2017 Dec; 70(6):844-858. PubMed ID: 29029808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment.
    Daly K; Farrington E
    J Pediatr Health Care; 2013; 27(6):486-96; quiz 497-8. PubMed ID: 24139581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Potassium Homeostasis in CKD.
    DuBose TD
    Adv Chronic Kidney Dis; 2017 Sep; 24(5):305-314. PubMed ID: 29031357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.
    Bridgeman MB; Shah M; Foote E
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii45-iii50. PubMed ID: 31800078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapies for hyperkalemia.
    Leon SJ; Harasemiw O; Tangri N
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):238-244. PubMed ID: 30865167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.
    Packham DK; Kosiborod M
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):567-73. PubMed ID: 26998854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z; Peacock WF; LoVecchio F; Levy PD
    Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.